Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombolytics and their use].

M C Alessi1, I Juhan-Vague

  • 1Laboratoire d'hématologie Hôpital de La Timone, Marseille.

La Revue Du Praticien
|December 3, 1999
PubMed
Summary
This summary is machine-generated.

Thrombolytic drugs activate plasminogen to plasmin for clot dissolution. While streptokinase is common, newer agents offer limited bleeding risk improvement, necessitating careful monitoring of fibrinolysis and anticoagulation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Augmenting pharmacotherapy with neuromodulation techniques for the treatment of bipolar disorder: a focus on the effects of mood stabilizers on cortical excitability.

Expert opinion on pharmacotherapy·2019
Same author

Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.

Scientific reports·2019
Same author

Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk.

Scientific reports·2017
Same author

α<sub>1</sub> -antitrypsin Pittsburgh and plasmin-mediated proteolysis.

Journal of thrombosis and haemostasis : JTH·2016
Same author

[Diagnosis of inherited thrombocytopenia].

La Revue de medecine interne·2015
Same author

Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-NImes prediction model.

Journal of thrombosis and haemostasis : JTH·2014
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Context:

  • Thrombolytic therapy is crucial for treating thrombotic events.
  • Plasmin is the active enzyme responsible for clot breakdown.
  • Streptokinase has been a traditional reference thrombolytic agent.

Purpose:

  • To review the mechanisms and clinical utility of various thrombolytic agents.
  • To compare the efficacy and safety profiles of different thrombolytics.
  • To highlight the role of haemostasis monitoring in thrombolytic therapy.

Summary:

  • Thrombolytic agents convert plasminogen to plasmin. Streptokinase, a non-enzyme protein, is immunogenic and can be neutralized by antibodies, causing systemic fibrinolysis.
  • Anisoylated streptokinase-plasminogen complex and urokinase show no significant advantages over streptokinase.

Related Experiment Videos

  • Fibrin-specific agents like tissue plasminogen activator and prourokinase do not reduce bleeding risk (e.g., 0.75% in brain).
  • Haemostasis surveys aid in controlling bleeding by quantifying drug-induced fibrinolytic activity and monitoring heparin-induced anticoagulation.

    • Impact:

    • Provides a comparative overview of thrombolytic agents, aiding clinical decision-making.
    • Emphasizes the limitations of current thrombolytics regarding bleeding risk.
    • Underscores the importance of haemostasis monitoring for safe and effective thrombolysis.